Physician profile
Magi Khalil
NPI 1700948635
$1,762.80
in general payments reported to CMS, 2019-2025
23 companies · $293 in 2025
The $293 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $274 · 2020: $175 · 2021: $247 · 2022: $264 · 2023: $242 · 2024: $267 · 2025: $293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $783 · Education: $18.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $783.18 |
| Education | $18.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $377.61 | 2019-2025 | Tecvayli, Darzalex, Talvey |
| Abbvie INC. | $209.04 | 2020-2025 | |
| Seagen INC. | $160.98 | 2019-2022 | |
| Pfizer INC. | $115.85 | 2023-2025 | |
| Gilead Sciences, INC. | $115.09 | 2021-2024 | Trodelvy |
| Genzyme Corporation | $103.81 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $85.15 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $74.98 | 2019-2024 | |
| Array Biopharma INC | $68.61 | 2023-2025 | Braftovi, Mektovi, Lorbrena |
| Eisai INC. | $64.11 | 2022-2024 | |
| Beigene USA, INC. | $53.86 | 2023-2024 | Brukinsa |
| Foundation Medicine, INC. | $49.98 | 2019 | |
| Puma Biotechnology, INC. | $44.75 | 2019-2021 | |
| Genentech USA, INC. | $39.61 | 2019-2020 | |
| Celgene Corporation | $39.34 | 2019-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $36.67 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $29.45 | 2021-2022 | |
| Stemline Therapeutics INC. | $21.32 | 2023 | Orserdu |
| Regeneron Healthcare Solutions, INC. | $16.19 | 2021 | |
| Incyte Corporation | $15.29 | 2021 | |
| Taiho Oncology, INC. | $14.90 | 2022 | |
| Agios Pharmaceuticals, INC. | $14.24 | 2019 | |
| Exelixis INC. | $11.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Magi Khalil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.